Tuesday, December 11, 2007

HAART Treatment CUTS RISK of Transmission BY 80% in HIV+ & hiv- COUPLES-study finds







HIV treatment dramatically cuts risk of HIV transmission in steady heterosexual
Michael Carter, Tuesday, August 30, 2005
Effective anti-HIV treatment has significantly reduced the sexual transmission of HIV amongst steady heterosexual couples, according to the results of a Spanish study published in the September 1st edition of the Journal of Acquired Immune Deficiency Syndromes. The investigators found that HIV prevalence amongst the initially HIV-negative partners fell from 10% before potent HIV therapy became available to 2% after the introduction of effective antiretroviral treatment. In addition, the investigators also noted that not a single case of HIV transmission occurred in a couple where the HIV-positive partner was taking a powerful combination of anti-HIV drugs.

Even though the study demonstrated the ability of HIV therapy to reduce heterosexual transmission by 80%, the investigators caution that even a small increase in sexual risk-taking could cancel this out and emphasise “the main preventative measure for HIV sexual transmission remains the avoidance of risky sexual practices.”

It is well known that a number of factors can influence the risk of HIV being transmitted during sex. These include sexual practices, stage of HIV infection, the presence of sexually transmitted infections, and the HIV viral load in the infected partner.

Antiretroviral therapy has the potential to dramatically reduce viral load, and the ability of anti-HIV treatment to reduce the infectiousness of HIV-positive individuals has been demonstrated by the use of antiretroviral drugs to prevent mother-to-child transmission of HIV.

The potential for antiretroviral drugs to reduce the risk of sexual transmission of HIV has not been well studied. Therefore investigators from Madrid designed a study looking at HIV prevalence amongst first-time HIV testers whose only risk factor for infection was having a steady heterosexual HIV-positive partner. The investigators compared HIV prevalence amongst individuals recruited before effective anti-HIV treatment became available and those who entered the study when potent HIV therapy was being used.

Since 1987 a specialist clinic in Madrid has been offering counselling and HIV testing for serodiscordant couples. A total of 393 couples using this clinic were included in a prospective observational study to determine HIV transmission risks. Couples were recruited between 1991 and 2003.

Social, demographic and sexual histories were obtained from both partners during structured interviews. Blood tests were performed on the HIV-positive partner to determine CD4 cell count and viral load.

Depending on their date of recruitment, the couples were allocated into one of three groups (1991 - 1995, pre-HAART; 1996 - 1998, early-HAART; 1999 onwards, late-HAART).

In the period before effective anti-HIV therapy became available, the HIV prevalence rate amongst the partners of the patient initially testing HIV-positive was 11%. This fell to 7% in the two years after potent anti-HIV treatment first became available, falling to 2% from 1999 onwards. This fall was statistically significant (p = 0.025).

The investigators found that HIV was only transmitted by patients who were not taking anti-HIV therapy. Not a single partner of an HIV-positive patient taking anti-HIV therapy became infected with HIV.

Other factors associated with HIV transmission were unprotected sex within the past six months (p = 0.048) and a CD4 cell count below 350 cells/mm3 in the HIV-positive partner (p = 0.025).

The prevalence of sexually transmitted infections in the partner who was initially diagnosed with HIV fell from 10% in the pre-HAART era to 1% between 1999 and 2003, and the presence of a sexually transmitted infection was not found to have a statistically significant association with the risks of HIV transmission.

The investigators conclude, “after the introduction of HAART, an important decrease in HIV transmission has been observed in a thoroughly studied group of steady heterosexual couples, irrespective of any changes in other factors that could affect transmission. These results strongly suggest that combined antiretroviral treatments applied according to current guidelines have a great potential for preventing HIV transmission.” The suggest that “accessibility to HAART...as long as it is not accompanied by a relaxation in other prevention measures, could greatly contribute to controlling the spread of HIV”.

Sunday, November 04, 2007

BEST ANSWER TOQ=WHATS YOUR JOB & DO U LIKE IT?

I am on disability pension but do HIV-AIDS Education & Awareness & Living with HIV Talks at local places of education & i do out-reach work at night.I am always happy to do the talks,afterwords is cool as 9/10 all the students will come up & continue to ask Q ,saying how it takes guts to stand in front of a class & tell your life story & to keep up the great work on staying clean off of coke heroin & speed.(3 yrs) & so where i once was part of the problem i am now part of the solution.My faith in GOD & Jesus was not misplaced,& so i take 1 day at a time.i forgot to mention that i did have hep-c but found out recntly that i am no longer hep-c +!!!i Thank GOD EVERYDAY!!

* 1 week ago

Source(s):
me,myself & i,gratefull recovering coke,heroin&speed addict with 3 yrs clean.HIV+ 2001,ohya cured of hep-c in 07!

* 0 Rating: Good Answer
* 0 Rating: Bad Answer
* Report It

Asker's Rating:
5 out of 5
Asker's Comment:
thanks for all the reply's .......they all sound interesting .......but i have 2 choose this answer .......cause i couldnt do this job knowing i had hiv ............you are braver than i would be tc xxx

Thursday, November 01, 2007

SELENIUM CHEAP SUPPLEMENT THAT WORKS SLOWING DOWN HIV VIRUS-STUDY FINDS!

Selenium supplementation slows HIV progression
November 1, 2007

This study looked specifically at selenium supplementation and how it affects progression of HIV. (As usual, the scientific evidence builds up over time: earlier research had already produced some findings about the role of selenium in immune system function, and its potential benefit for people with HIV.)

The 2007 finding: a daily supplement of selenium can “suppress the progression of HIV-1 viral burden and provide indirect improvement of CD4 count.” And the study results “support the use of selenium as a simple, inexpensive, and safe adjunct therapy in HIV spectrum disease.”

Interestingly, the study found that selenium supplementation was beneficial regardless of factors such as past drug use, time since HIV diagnosis, adherence to antiretroviral medication, and infection with hepatitis C. So–a very general usefulness for this supplement for slowing progression of HIV.


“Suppression of Human Immunodeficiency Virus Type 1 Viral Load With Selenium Supplementation.”
Barry E. Hurwitz; Johanna R. Klaus; Maria M. Llabre; Alex Gonzalez; Peter J. Lawrence; Kevin J. Maher; Jeffrey M. Greeson; Marianna K. Baum; Gail Shor- Posner; Jay S. Skyler; Neil Schneiderman.
Arch Intern Med. 2007;167:148-154.

Friday, September 28, 2007

MEDICAL POT NEEDS EASIER ACCESS,SUDBURY NEEDS COMPASSION CLUB!






CANCER 7 HIV PAIENTS NEED A COMPASION CLUB HERE IN THE SUDBURY AREA,BIGTIME.AFTER ALL WE DO HAVE THE ONLY CANCER TRTEATMENT CENTRE IN THER NORTH EH!